Tag: release

佛羅里達州邁阿密, June 13, 2026 (GLOBE NEWSWIRE) -- 預期 SpaceX (NASDAQ: SPCX) 今日將於 Nasdaq 開始買賣，Defiance ETFs 確認，Defiance Daily 2X Space ETF (Cboe: SPCL) 會在其投資組合中尋求對 SpaceX A 類普通股提供 2 倍每日槓桿曝險，令其成為首隻及唯一在上市首日提供 2 倍 SpaceX 曝險的美國交易所買賣基金 (ETF)。該基金以 135 美元的首次公開招股 (IPO) 價建立其 SpaceX 曝險。

미국 플로리다주 마이애미, June 13, 2026 (GLOBE NEWSWIRE) -- 우주항공기업 스페이스X(SpaceX)가 오늘 나스닥에서 종목코드 SPCX로 거래를 시작할 것으로 예상되는 가운데, Defiance ETFs는 자사의 ‘Defiance Daily 2X Space ETF (Cboe: SPCL)’가 포트폴리오 내에서 스페이스X 클래스A 보통주에 대해 일일 기준 2배 레버리지 수익률을 추종할 계획이라고 밝혔다. 이에 따라 이 ETF는 스페이스X 상장 첫날부터 스페이스X 주식에 대한 2배 레버리지 노출을 제공하는 미국 최초이자 유일한 ETF가 됐다. 펀드의 스페이스X 투자 비중은 기업공개(IPO) 공모가인 주당 135달러를 기준으로 설정됐다.

フロリダ州マイアミ発, June 13, 2026 (GLOBE NEWSWIRE) -- スペースX (SpaceX) (NASDAQ: SPCX) が本日NASDAQでの取引を開始する見込みであり、ディファイアンスETFs (Defiance ETFs) は、ディファイアンス・デイリー2XスペースETF (Defiance Daily 2X Space ETF) (Cboe: SPCL) がそのポートフォリオ内で、スペースXのクラスA普通株に対し、1日あたり2倍のレバレッジをかけたエクスポージャーを目指すことを確認した。このことにより、同ETFはIPO当日にスペースXへの2倍のエクスポージャーが設定されている、米国初かつ唯一のETFとなる。同ファンドのスペースXへのエクスポージャーは、IPO価格135ドル (約21,600円) に設定された。

佛罗里达州迈阿密, June 13, 2026 (GLOBE NEWSWIRE) -- 随着 SpaceX (纳斯达克代码：SPCX) 预计今日在纳斯达克开始交易，Defiance ETFs 证实，旗下 Defiance Daily 2X Space ETF (芝加哥期权交易所代码：SPCL) 将寻求在其投资组合中对 SpaceX A 类普通股提供 2 倍每日杠杆风险敞口。这使得该基金成为 SpaceX 上市首日首个也是唯一一个提供 2 倍杠杆风险敞口的美国 ETF。该基金按照 135 美元的 IPO 发行价确定了对 SpaceX 的风险敞口。

BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.